Diabetes Research and Clinical Practice
Volume 61 , Pages S3-S8 , July 2003

Managing diabetes: what to do about cardiovascular disease

References 

  1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. J. Am. Med. Assoc. 2002;287:2570–2581
  2. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. New Engl. J. Med. 1998;339:229–234
  3. Miettinen H, Lehto S, Salomaa V, et al.  Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. Diabetes Care. 1998;21:69–75
  4. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group, Lancet 352(9131) (1998) 854–865.
  5. Stevens R, Kothari V, Adler AI, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin. Sci. 2001;101:671–679
  6. Haffner SM, Miettinen H, Stern MP. Relatively more atherogenic coronary heart disease risk factors in prediabetic women than in prediabetic men. Diabetologia. 1997;40:711–717
  7. Koenig W, Sund M, Frohlich M, et al.  C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Circulation. 1999;99:237–242
  8. Pickup JC, Mattock MB, Chusney GD, et al.  NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40:1286–1292
  9. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. 2000;321(7258):405–412
  10. Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care. 2002;25(5):894–899
  11. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225–232
  12. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and non-diabetic individuals. J. Am. Med. Assoc. 2001;286(4):421–426
  13. Heart Protection Study Collaborative Group . MRC/BHF Heart Protection Study: randomised placebo-controlled trial of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22
  14. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators, Lancet 355 (2000) 253–259.
  15. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837–853.
  16. Adler AI. Cardiovascular risk reduction in diabetes: underemphasized and overdue. Messages from major trials. Clin. Med. JRCPL. 2001;1:472–477
  17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 2001;285:2486–2497
  18. Wood D, De Backer G, Faergeman O, et al.  Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis. 1998;140:199–270
  19. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT), J. Am. Med. Assoc. 288(23) (2002) 2998–3007.
  20. US Preventive Services Task Force . Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann. Intern. Med. 2002;136:157–160
  21. Aspirin therapy in diabetes. Position statement of the American Diabetes Association, Diabetes Care 25 (2002) S78-S79.
  22. Schwartz L, Kip KE, Frye RL, Alderman EL, Schaff HV, Detre KM. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation. 2002;106(21):2652–2658
  23. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular disease, Circulation 106 (2002) 388–391.
  24. Pyörälä K, Pedersen TR, Kjekshus J, et al.  Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care. 1997;20:614–620
  25. Collins R. Heart Protection Study. Oxford, England: Oxford University Press; 2001;
  26. Taskinen M-R, Greenwood R, Heine R, et al.  Dyslipidaemia in type 2 diabetes: a panel discussion. Pract. Diab. Int. 2002;19(suppl):S1–S6
  27. Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl. J. Med. 2002;393:393–403
  28. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077
  29. American Diabetes Association . Management of dyslipidemia in adults with diabetes. Diabetes Care. 2001;24(suppl 1):S58–S61

PII: S0168-8227(03)00127-X

doi: 10.1016/S0168-8227(03)00127-X

Diabetes Research and Clinical Practice
Volume 61 , Pages S3-S8 , July 2003

Article Tools

* Image Usage & Resolution